Want to see ALKS full AI Analyst Report?

Alkermes (ALKS) Earnings Dates, Call Summary & Reports

632 Followers

Earnings Data

Report Date

Jul 29, 2026

Before Open (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

-0.02

Last Year’s EPS

0.67

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 11 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:May 05, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call communicated strong commercial momentum, sizable year-over-year revenue growth (+38% for proprietary products), an encouraging early LUMRYZ launch with meaningful sales and patient growth, a material adjusted EBITDA beat, and clear pipeline progress with Phase III initiation and multiple new programs underway. Offsetting factors include a GAAP net loss and negative GAAP EBITDA in the quarter, elevated R&D and SG&A as programs scale and integration costs are realized, increased leverage and near-term margin pressure from inventory step-up and widening gross-to-net. On balance, the positives (revenue growth, LUMRYZ contribution, adjusted EBITDA beat, improved purchase price accounting and an expanding orexin pipeline) meaningfully outweigh the near-term financial and execution headwinds.

Company Guidance

Alkermes updated 2026 outlook and Q2 guidance: full‑year revenue is expected to exceed $1.7 billion with adjusted EBITDA greater than $370 million, GAAP net loss of $70–90 million and GAAP EBITDA of $105–135 million; 2026 COGS is now expected at $320–340 million (including an updated LUMRYZ inventory step‑up of ~ $105 million vs prior ~$150M) and intangible amortization of $75–85 million (formerly $95–105M), and no income tax benefit is now expected (prior ~$20M). Product-level guidance is VIVITROL $460–480M, ARISTADA $365–385M, LYBALVI $380–400M, and LUMRYZ total net sales $350–370M (Alkermes to record $315–335M reflecting the mid‑Feb close). Q2 outlook: proprietary portfolio net sales $385–405M (including a full quarter of LUMRYZ), COGS $85–95M, R&D $110–120M, SG&A $210–220M and Q2 adjusted EBITDA $100–120M. Q1 actuals included total revenues $392.9M, proprietary product sales $338.1M, manufacturing/royalty revenue $54.8M, Q1 COGS $61.6M (would be $48.9M net of LUMRYZ step‑up), R&D $103.3M, SG&A $264.6M (including ~$55M one‑time Avadel costs), GAAP net loss $66.5M, EBITDA –$30.1M and adjusted EBITDA $80.3M; Q1 brand detail: VIVITROL $112.4M, ARISTADA $93.8M, LYBALVI $92.4M (TRx +21% y/y; gross‑to‑net ~33%), LUMRYZ ≈$72M for the quarter (≈$39.5M in the first 6 weeks) with ~3,600 patients on therapy, and cash & investments of ≈$538M.

Strong Topline Growth

Net sales from proprietary products increased 38% year-over-year to $338.1 million in Q1 2026, contributing to total revenues of $392.9 million for the quarter.

Robust Performance Across Key Brands

VIVITROL Q1 net sales of $112.4M (2026 guidance $460M–$480M); ARISTADA Q1 net sales of $93.8M (2026 guidance $365M–$385M); LYBALVI Q1 net sales of $92.4M, up 32% YoY with TRX growth of 21% YoY and 2026 guidance $380M–$400M.

Successful Acquisition and LUMRYZ Launch Momentum

Closed Avadel acquisition mid-February. LUMRYZ recorded approximately $39.5M of net sales in the 6 weeks post-close and ~ $72M for the full quarter reported; exited the quarter with ~3,600 patients on therapy (brand patient count growth ~28% YoY). Full-year LUMRYZ net sales guidance $350M–$370M (Alkermes share $315M–$335M).

Adjusted EBITDA Beat and Improved Near-Term Outlook

Generated adjusted EBITDA of $80.3M in Q1, well above prior Q1 guidance of $30M–$50M; Q2 adjusted EBITDA expected $100M–$120M. Full-year EBITDA outlook improved to positive $105M–$135M after purchase price accounting refinements.

Purchase Price Accounting Refinements Reduced Expected Charges

Inventory step-up expense for LUMRYZ now expected ~$105M in 2026 (vs prior ~$150M), lowering expected 2026 COGS to $320M–$340M (from prior $365M–$385M). Full-year amortization of intangibles revised down to $75M–$85M (from $95M–$105M).

Progressing a Broad Orexin Pipeline

Alixorexton Brilliance Phase III is open for enrollment in NT1 and NT2; Vibrance-2 (NT2) data to be presented in June; Vibrance-3 (IH) Phase II on track to complete in Q4. New molecules ALKS 7290 (ADHD) and ALKS 4510 (fatigue in MS/Parkinson’s) advancing—Phase Ib ADHD data expected Q4 2026 and Phase II (~300 pts) planned for 2026/2027.

Balance Sheet Actions and Share Repurchase

Ended Q1 with ~$538M cash and investments after deploying ~$775M cash toward Avadel acquisition and entering $1.525B term loans due 2031; repurchased ~1M shares for $28M with $172M remaining authorization.

Alkermes (ALKS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALKS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 29, 2026	2026 (Q2)	-0.02 / -	0.668	―	―	―
May 05, 2026	2026 (Q1)	-0.55 / -0.40	0.265	-250.94% (-0.67)
Feb 25, 2026	2025 (Q4)	0.41 / 0.29	1.05	-72.38% (-0.76)
Oct 28, 2025	2025 (Q3)	0.37 / 0.68	0.72	-5.00% (-0.04)
Jul 29, 2025	2025 (Q2)	0.38 / 0.67	0.7	-4.57% (-0.03)
May 01, 2025	2025 (Q1)	0.25 / 0.27	0.43	-38.37% (-0.16)
Feb 12, 2025	2024 (Q4)	0.77 / 1.05	0.22	377.27% (+0.83)
Oct 24, 2024	2024 (Q3)	0.72 / 0.72	0.595	21.01% (+0.13)
Jul 24, 2024	2024 (Q2)	0.70 / 0.70	0.511	36.99% (+0.19)
May 01, 2024	2024 (Q1)	0.58 / 0.43	0.009	4677.78% (+0.42)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALKS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 05, 2026	$34.17	$36.25	+6.09%
Feb 25, 2026	$33.39	$31.04	-7.04%
Oct 28, 2025	$29.72	$31.00	+4.31%
Jul 29, 2025	$26.15	$27.00	+3.25%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Alkermes plc (ALKS) report earnings?

Alkermes plc (ALKS) is schdueled to report earning on Jul 29, 2026, Before Open (Confirmed).

What is Alkermes plc (ALKS) earnings time?

Alkermes plc (ALKS) earnings time is at Jul 29, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALKS EPS forecast?

ALKS EPS forecast for the fiscal quarter 2026 (Q2) is -0.02.